Cellectis (NASDAQ: CLLS) was the hardest-hit European name trading in the United States on Thursday, shedding 8.43% during late morning trading on November 19, 2026.

The French gene-editing company’s sharp drop stood well above the losses recorded by other European equities listed as American Depositary Receipts on U.S. exchanges.

Nokia (NYSE: NOK) was the second-largest decliner among the group, falling 3.86% as investors moved away from the Finnish telecommunications equipment maker.

BP (NYSE: BP), the British energy giant, also traded lower, declining 0.53% during the same late-morning window.

The losses across these three names contributed to a broader softening in European ADRs during Thursday’s session, with selling pressure evident across multiple sectors and geographies.

DBV Technologies (NASDAQ: DBVT) and Foce (NASDAQ: FOCL) were flat on the day, registering no movement as of the late-morning snapshot.

The contrast between the steep losses in CLLS and NOK and the inactivity of DBVT and FOCL illustrated an uneven trading environment for European names seeking U.S. capital.

American Depositary Receipts allow U.S. investors to hold shares of foreign companies without navigating overseas exchanges, making them a widely watched barometer of international sentiment among domestic portfolios.

Thursday’s broad-based weakness across multiple European ADRs suggested that risk appetite for non-U.S. equities remained under pressure heading into the latter part of the trading week.

The session’s moves came as global markets continued to process a range of macroeconomic signals, with European names particularly sensitive to currency movements and regional economic data.

Cellectis, Nokia, and BP together represented the clearest signs of selling in the European ADR space, with their combined declines reflecting caution among U.S.-based investors toward international holdings on the day.